Collective data support NEPC arising as a mechanism of resistance to AR therapies with loss of AR protein expression and/or canonical AR signaling in NEPC tumors and acquisition of alternative lineage programs that drive tumor growth (5, 8–12). This evidence concerns the gene AR and neoplasm.